In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Cassava Sciences (SAVA – Research Report), with a price target of $75.00. The company’s shares opened today at $20.66.
According to TipRanks, Roy is a 3-star analyst with an average return of -4.9% and a 26.79% success rate. Roy covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, Oncolytics Biotech, and Cassava Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cassava Sciences with a $99.50 average price target.
See today’s best-performing stocks on TipRanks >>
SAVA market cap is currently $911.8M and has a P/E ratio of -10.29.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SAVA in relation to earlier this year. Most recently, in June 2023, Patrick Phd Scannon, a Director at SAVA bought 1,000.00 shares for a total of $950.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
Read More on SAVA:
- Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
- Cassava Sciences call volume above normal and directionally bullish
- Biotech Alert: Searches spiking for these stocks today
- H.C. Wainwright reiterates Buy rating, $124 target on Cassava after AD data
- Cassava Sciences Plunges despite Solid Drug Study
